Repligen Corp (RGEN)

29.88
1.10 3.40
NASDAQ : Health Care
Prev Close 30.93
Open 30.74
Day Low/High 29.84 / 31.81
52 Wk Low/High 20.07 / 39.17
Volume 44.14K
Avg Volume 248.90K
Exchange NASDAQ
Shares Outstanding 33.83M
Market Cap 1.05B
EPS 0.30
P/E Ratio 147.29
Div & Yield N.A. (N.A)

Latest News

UPDATE -- Repligen Acquires TangenX Technology Corporation

UPDATE -- Repligen Acquires TangenX Technology Corporation

Adds innovative single-use Sius™ TFF technology to downstream bioprocessing portfolio

Repligen Acquires TangenX Technology Corporation

Repligen Acquires TangenX Technology Corporation

Adds innovative single-use Sius™ TFF technology to downstream bioprocessing portfolio

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

Repligen is Now Oversold (RGEN)

Repligen is Now Oversold (RGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Repligen (RGEN) Shares Cross Below 200 DMA

Repligen (RGEN) Shares Cross Below 200 DMA

In trading on Thursday, shares of Repligen Corp. crossed below their 200 day moving average of $27.23, changing hands as low as $26.59 per share.

Repligen Reports Third Quarter 2016 Financial Results

Repligen Reports Third Quarter 2016 Financial Results

Third quarter 2016 revenue of $24.7 million reflects 25% year-over-year growth

Repligen To Report Third Quarter 2016 Financial Results

Repligen To Report Third Quarter 2016 Financial Results

Webcast and Conference Call to Be Held Thursday, November 3, 8:30 a.m. ET

Repligen Has More Upside Ahead

Add to longs on a short-term correction.

Commit To Buy Repligen Corp. At $25, Earn 12.9% Annualized Using Options

Commit To Buy Repligen Corp. At $25, Earn 12.9% Annualized Using Options

Investors considering a purchase of Repligen Corp. shares, but cautious about paying the going market price of $29.49/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Repligen Reports Second Quarter 2016 Financial Results

Repligen Reports Second Quarter 2016 Financial Results

Exceptional second quarter puts Company on track for 21%+ revenue growth for 2016

Short Interest Moves 24% Higher For RGEN

Short Interest Moves 24% Higher For RGEN

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 602,565 share increase in total short interest for Repligen Corp. , to 3,098,037, an increase of 24.15% since 06/30/2016.

Repligen To Report Second Quarter 2016 Financial Results

Repligen To Report Second Quarter 2016 Financial Results

Webcast and Conference Call to Be Held Thursday, August 4, 8:30 a.m. ET

Repligen is Now Oversold (RGEN)

Repligen is Now Oversold (RGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Repligen Corp. At $22.50, Earn 18.1% Annualized Using Options

Commit To Buy Repligen Corp. At $22.50, Earn 18.1% Annualized Using Options

Investors eyeing a purchase of Repligen Corp. stock, but cautious about paying the going market price of $26.29/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Repligen Reports First Quarter 2016 Financial Results

Repligen Reports First Quarter 2016 Financial Results

Record quarterly revenue of $25.1 million, reflecting 21% year-over-year growth

Repligen To Report First Quarter 2016 Financial Results

Repligen To Report First Quarter 2016 Financial Results

Webcast and Conference Call to Be Held Thursday, May 5, 8:30 a.m. ET

Repligen Acquires Atoll GmbH

Repligen Acquires Atoll GmbH

Broadens portfolio, expands customer base and increases capabilities in growing pre-packed chromatography column market

Repligen Forms Scientific Advisory Board

Repligen Forms Scientific Advisory Board

Recognized Experts in Bioprocessing to Provide Input on Product Innovation and Portfolio Expansion for Repligen

April Corrections Bring … Well, Let's Concentrate on April

I have a plethora of indicators that say we should get some sort of correction.